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A fundamental concept of treatment is to do no harm.However,
with cancer treatment this is not always possible.
Chemotherapy is associated with cardiovascular (CV)
complications.
1,2 This risk is evengreater in the elderly patients
and patients with established CV disease. More specifically,
tachyarrhythmias (eg, cisplatin), bradyarrythmias (eg, pacli-
taxel), or QT prolongation (eg, dasatinib) have been reported.
Furthermore, myocardial necrosis, coronary vaso-occlusion
or vasospasm, pericardial disease (eg, cytarabine), endocardial
fibrosis (eg, busulfan), and heart failure can occur. Hypoten-
sion (eg, fludarabine) or hypertension (eg, vinca alkaloids) has
also been reported.
1,2 Cardiotoxicity, endothelial injury, and
Takotsubo syndrome have been reported in patients treated
with 5-fluorouracil (5-FU).
3-5 Cardiotoxicity to 5-FU was
reported 35 years ago.
3-5 Cardiotoxicity of chemotherapy has
been reported in patients ranging from children through adults
(eg, with anthracyclines or cisplatin).
6 Adriamycin-induced
myocyte damage has been attributed to the production of toxic
oxygen free radicals.
7 This can cause lipid peroxidation of
membranes resulting in vacuolation, irreversible damage, and
myocyte replacement by fibrous tissue.
7
The use of angiogenesis inhibitors in cancer therapy is
expanding as are the associated adverse CV effects (eg, hyper-
tension, thromboembolism, left ventricular dysfunction, and
QTc prolongation).
2,8 Vascular endothelial growth factor
(VEGF) plays a role in maintaining vascular homeostasis via
the production of the vasodilator nitric oxide (NO) and
decreased vascular resistance through the generation of new
blood vessels.
2,8 Therefore, it is not surprising that inhibition
of VEGF signaling (eg, by bevacizumab, aflibercept, sorafenib,
sunitinib, pazopanib, vandetanib, axitinib, regorafenib, or
cabozantinib) can be associated with hypertension.
2,8 An
increased risk of arterial thromboembolic events has also been
linked to the use of bevacizumab, aflibercept, and a number of
the antiangiogenic tyrosine kinase inhibitors.
2,8
The risk of thrombotic events is increased in patients with
malignant disease.
9 The proposed mechanisms include release
of procoagulants by tumor cells (tissue factor or tumor cells
dying as a result of treatment) and expression of procoagulant
activity by normal host cells such as monocytes, platelets, and
endothelial cells.
9 Furthermore, surgery, chemotherapy, indwel-
lingcentralvenouscatheters,plateletactivation,reducedfibrino-
lytic activity, decreases in proteins C and S, endothelial cell
injury as well as disease- and patient-specific risk factors may
contribute to the risk of thrombosis.
Hormonal agents are used for the treatment of cancer.
10
Compared with aromatase inhibitors, tamoxifen use is associ-
ated with a higher rate of venous thromboembolic events but
possibly with decreased odds of developing CV disease.
11
Tamoxifen is an antiestrogen with weak estrogenic effects that
may contribute to its prothrombotic activity. Tamoxifen raises
triglyceride (TG) levels and increases the risk of acute pancrea-
titis.
10 Other agents used in estrogen receptor-positive breast
cancer such as toremifene (a selective estrogen receptor
modulator) show reduction in total cholesterol, low-density
lipoprotein cholesterol, and TGs.
12 The lipid effects of these
drugs and their potential effect on the risk of cardiac events are
complex and beyond the scope of this editorial.
Mediastinal radiotherapy (especially to the left chest) can
damage virtually any component of the heart, including the
pericardium, myocardium, valves, coronary arteries, capil-
laries, and conducting system.
13-17 Pericarditis is the typical
acute manifestation of radiation injury, while chronic pericar-
dial disease, coronary heart disease (CHD), cardiomyopathy,
valvular disease, and conduction abnormalities can appear
years or decades later.
13-17 The lesions leading to diseases
exhibit typical features of atherosclerosis, including lipid accu-
mulation, inflammation, and thrombosis.
13-17 Moreover, the
presence of vascular risk factors (eg, smoking and dyslipide-
mia) may increase the risk of cardiotoxicity following radiation
therapy.
15 The pathophysiologic pathway responsible for most
manifestations of cardiotoxicity appears to involve damage to
blood vessels.
13-17 The histological hallmarks of radiation-
associated cardiotoxicity are diffuse fibrosis in the interstitium
of the myocardium with normal-appearing myocytes and
narrowing of capillary and arterial lumens.
13-17 Conduction
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13-17 There-
fore, it is not surprising that recent guidelines state that radio-
therapy may increase the incidence of CHD and stroke.
14
Surprisingly, these guidelines do not consider the possibility
of increased cardiac harm when patients receive chemotherapy
or both radiotherapy and chemotherapy.
15
The effect of radiation on arteries extends beyond the heart,
since similarities between irradiation-induced, plaque-like
carotid artery stenosis and arterial changes occurring in
hypercholesterolemia have been reported.
18,19 Furthermore,
Kilicaslan et al in this issue of Angiology report that radiother-
apy is associated with impaired aortic elasticity and stiffness in
patients with breast cancer.
20 The authors also link this effect
with an increased risk of CHD.
Itisalsoclinicallyrelevantthatpatientswithperipheralarterial
disease, abdominal aortic aneurysms, and carotid artery stenosis
are atincreasedriskofdevelopinglung andother cancers.
21This
maybeduetosharingriskfactorssuchasageandsmokingwhile
delaying vascular death.
21 Thus, these patients combine a high
riskfor vascularevent aswell as cancer.
21The vascular risk may
be further aggravated by chemotherapy and/or radiotherapy.
21
Regardingthepreventionofadverse CV events,the earlyrec-
ognition of subclinical cardiotoxicity by noninvasive monitoring
(eg, echocardiography, Holter monitoring, cardiac magnetic
resonance imaging, brain natriuretic peptide, and troponin lev-
els) may prove useful.
1 The presence of other risk factors for
CHD (eg, hypertension and smoking) as well as the younger age
of the patients, in relation to the total radiation dose, the dose per
fraction, volume of heart irradiated, and the concomitant admin-
istrationofcardiotoxicsystemicagents,influencetheprobability
of cardiotoxicity after radiation therapy.
13-17 Because estab-
lished CHD risk factors (eg, smoking, dyslipidemia, and hyper-
tension)may increasethe riskofradiation-induced heart disease,
efforts should be made to screen for and manage these risk fac-
tors.Thereisevenaninterestinthepreventionofchemotherapy-
induced left ventricular systolic dysfunction by administering
carvedilol together with enalapril just before starting chemother-
apy in patients with hematological malignancies.
22
Diabetes and metabolic syndrome are associated with an
increased risk of cancer and vascular events.
23,24 In turn, some
drugs used to treat vascular risk (eg, statins, aspirin, and
metformin) may have anticancer effects while other drugs may
potentially increase that risk.
25,26 However, a detailed discus-
sion of the interplay between diseases (and their treatment)
associated with an increased risk of cancer as well as vascular
events is beyond the scope of this editorial.
We suggest that there is a need for specific guidelines for the
management of vascular risk in patients who have malignant
disease and have been treated with chemotherapy and/or radio-
therapy. In this context, others have suggested the need for
improved interaction between cardiology and oncology and
creating a cardio-oncologist ‘‘specialty.’’
27 As treatment for
malignant disease becomes more successful, there will be an
increased number of patients at a higher risk of vascular events.
We need to avoid patients surviving cancer only to die soon
after from ‘‘iatrogenic’’ vascular disease!
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